167 related articles for article (PubMed ID: 7791516)
1. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
Kroemer HK; Eichelbaum M
Life Sci; 1995; 56(26):2285-98. PubMed ID: 7791516
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
3. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
Wolf CR
IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.
Otton SV; Schadel M; Cheung SW; Kaplan HL; Busto UE; Sellers EM
Clin Pharmacol Ther; 1993 Nov; 54(5):463-72. PubMed ID: 7693389
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
[TBL] [Abstract][Full Text] [Related]
8. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquin oxidation genotype and susceptibility to lung cancer.
Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
[TBL] [Abstract][Full Text] [Related]
11. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
12. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM
Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
[TBL] [Abstract][Full Text] [Related]
15. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
18. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
[TBL] [Abstract][Full Text] [Related]
20. Ethnic differences of the primary gene defect at the cytochrome P-450 2D6.
Katoh T; Higashi K
J UOEH; 1992 Sep; 14(3):205-9. PubMed ID: 1410938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]